… Cristina Fortuno and Kristy Lee contributed equally to this study. … and have previously
published assertions on TP53 variants: Cristina Fortuno, Phuong L. Mai, Laura D. Attardi, D. …

Background Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are
associated with increased breast cancer risk, but risks associated with missense variants in …

Pathogenic germline variants in TP53 predispose carriers to the multi‐cancer Li‐Fraumeni
syndrome (LFS). Widespread multigene panel testing is identifying TP53 pathogenic variants …

Primary ovarian insufficiency is one of the main causes of female infertility owing to an
abnormal ovarian reserve. Its relevance has increased in more recent years due to the fact that …

Clinical interpretation of germline missense variants represents a major challenge, including
those in the TP53 Li–Fraumeni syndrome gene. Bioinformatic prediction is a key part of …

Sharing genomic variant interpretations across laboratories promotes consistency in variant
assertions. A landscape analysis of Australian clinical genetic-testing laboratories in 2017 …

Background BRCA1/2 testing is crucial to guide clinical decisions in patients with hereditary
breast/ovarian cancer, but detection of variants of uncertain significance (VUSs) prevents …

Early onset breast cancer is the most common malignancy in women with Li‐Fraumeni
syndrome, caused by germline TP53 pathogenic variants. It has repeatedly been suggested that …

Germline pathogenic variants in the TP53 gene cause Li‐Fraumeni syndrome, a condition
that predisposes individuals to a wide range of cancer types. Identification of individuals …

Multigene panel testing has led to an increase in the number of variants of uncertain
significance identified in the TP53 gene, associated with Li‐Fraumeni syndrome. We previously …